Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 USD | -2.42% | -6.70% | -83.74% |
May. 14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
May. 10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
Evolution of the average Target Price on RAPT Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering RAPT Therapeutics, Inc.
Wolfe Research | |
Guggenheim | |
Barclays | |
JPMorgan Chase | |
UBS | |
Leerink Partners | |
HC Wainwright | |
Piper Sandler | |
Stifel Nicolaus | |
Cantor Fitzgerald | |
Evercore ISI | |
Berenberg Bank | |
Wells Fargo Securities | |
Goldman Sachs | |
Capital One Securities | |
SVB Securities LLC | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- RAPT Stock
- Consensus RAPT Therapeutics, Inc.